Shionogi & Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
11.9M | +58.60% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
10.9M | +0.18% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
7.2M | -3.61% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.0M | +2.59% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.2M | +1.41% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
2.7M | -0.16% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
282.3K | +4.30% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | +11.1% |
| 2021 | ¥36 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Approval Obtained for Domestic Manufacturing and Marketing of Depression Treatment Drug 'Zavege® Capsules 30mg'
Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.
Read more -
Notice Regarding the Acquisition of the Edaravone Business for the Treatment of Amyotrophic Lateral Sclerosis by Tanabe Pharma
Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.
Read more -
Regarding the Acquisition of Domestic Manufacturing and Marketing Approval for the Depression Treatment Drug "Zazvey® Capsules 30mg"
Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,572
Rating Score: - (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan.
